...ONC's OncorPharm affiliate acquired an option for an exclusive worldwide right to develop pharmaceuticals based on...
...the skin pigment melanin and the production of p53 protein, which helps suppress abnormal growth. OncorPharm...

...ONC's OncorPharm subsidiary acquired an exclusive worldwide license to diagnostic and therapeutic applications of a highly...
...pressure and arterial blockage. ONC plans to develop diagnostics to identify people with the mutation. OncorPharm...

...raise the question whether naturally occurring triple helixes are a source of genetic instabilty. ONC's OncorPharm Inc....

...which has a worldwide license to the patent, has sublicensed the therapeutic rights to its OncorPharm...
...develop genetic testing products from the technology and to provide other companies with limited sublicenses. OncorPharm...

...financing through a $3 million private placement (see page B9). Oncor Inc. (ONCR) ONCR formed OncorPharm Inc....